Latest Articles

  • Medical management of benign prostatic hyperplasia
    Eiftu S. Haile, MD, Ayodeji E. Sotimehin, MD and Bradley C. Gill, MD, MS
    Cleveland Clinic Journal of Medicine March 2024, 91 (3) 163-170; DOI: https://doi.org/10.3949/ccjm.91a.23027

    The goal is to maximize quality of life and minimize “bothersome” symptoms. Choices about medical therapy are guided by indication, effectiveness, side effects, as well as patient preference.

  • Is there a role for chronic suppressive therapy in herpes simplex virus infection?
    Sandhya R. Nagarakanti, MD, FIDSA and Ahmed M. Zikri, PharmD
    Cleveland Clinic Journal of Medicine March 2024, 91 (3) 151-153; DOI: https://doi.org/10.3949/ccjm.91a.23099

    Yes, in patients with recurrent oral and genital HSV-2 infection and oral HSV-1 infection.

  • Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
    Taher Modarressi, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 82; DOI: https://doi.org/10.3949/ccjm.91c.02001
  • Our Peer-Reviewers for 2023
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 85;
  • Does my patient have testosterone deficiency?
    Andrew D. Shumaker, MD, Navid Leelani, DO, Bradley Roth, Prajit Khooblall, MD, Raevti Bole, MD, Scott D. Lundy, MD, PhD and Petar Bajic, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 93-95; DOI: https://doi.org/10.3949/ccjm.91a.23064

    Diagnosis of testosterone deficiency requires the presence of relevant signs or symptoms along with biochemical evidence.

  • Dealing with the “T” (testosterone)
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 78-79; DOI: https://doi.org/10.3949/ccjm.91b.02024

    If a patient feels better when taking testosterone supplementation, is it the “T” or is it a placebo effect?

  • What are the management considerations for venous thromboembolic events in patients with cirrhosis?
    Marie M. Plante, MD, BSN, RN, Emily B. Wolf, MD and Razvan M. Chirila, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 86-88; DOI: https://doi.org/10.3949/ccjm.91a.23045

    The authors review the current evidence on venous thromboembolic event (VTE) risk prediction in patients with cirrhosis, as well as VTE prophylaxis and anticoagulant therapy.

  • In Reply: Surgical and procedural management of benign prostatic hyperplasia
    Ayodeji E. Sotimehin, MD and Bradley C. Gill, MD, MS
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 83-84; DOI: https://doi.org/10.3949/ccjm.91c.02004
  • Surgical and procedural management of benign prostatic hyperplasia
    Sameer Gadani, MD, Ihab Haddadin, MD, Justin Guan, MD, Michael Bergen, MD and Abraham Levitin, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 83; DOI: https://doi.org/10.3949/ccjm.91c.02003
  • Management of venous thromboembolism in patients with active cancer
    Heloni M. Dave, MBBS and Alok A. Khorana, MD, FACP, FASCO
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 109-117; DOI: https://doi.org/10.3949/ccjm.91a.23017

    The authors review the presentation and diagnosis of venous thromboembolism in patients with cancer and present an approach to treatment that aims to balance the bleeding risk from anticoagulation with the risk of recurrent thrombosis.

Pages